Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1 (Neuromuscular Disorders, 2018)

(untitled) - Holland, A; Varela, M; Hazell, G; Klein, A; Arzumanov, A; Raz, R; Gait, M; Furling, D; Wood, M